Mehran, Roxana; Cao, Davide; Angiolillo, Dominick J; Bangalore, Sripal; Bhatt, Deepak L; Ge, Junbo; Hermiller, James; Makkar, Raj R; Neumann, Franz-Josef; Saito, Shigeru; Picon, Hector; Toelg, Ralph; Maksoud, Aziz; Chehab, Bassem M; De la Torre Hernandez, Jose M; Kunadian, Vijay; Sardella, Gennaro; Thiele, Holger; Varenne, Olivier; Vranckx, Pascal; ... (2021). 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC. Cardiovascular Interventions, 14(17), pp. 1870-1883. Elsevier 10.1016/j.jcin.2021.07.016
|
Text
3-or.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
OBJECTIVES
The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI).
BACKGROUND
Current-generation drug-eluting stents are preferred over bare-metal stents for HBR patients, but their optimal DAPT management remains unknown.
METHODS
The XIENCE Short DAPT program included 3 prospective, multicenter, single-arm studies enrolling HBR patients who underwent successful PCI with a cobalt-chromium everolimus-eluting stent. After 1 month (XIENCE 28 USA and XIENCE 28 Global) or 3 months (XIENCE 90) of DAPT, event-free patients discontinued the P2Y12 inhibitor. The postmarketing approval XIENCE V USA study was used as historical control in a propensity score-stratified analysis.
RESULTS
A total of 3,652 patients were enrolled. The propensity-adjusted rate of the primary endpoint of all-cause mortality or myocardial infarction was 5.4% among 1,693 patients on 3-month DAPT versus 5.4% in the 12-month DAPT historical control (Pnoninferiority = 0.0063) and 3.5% among 1,392 patients on 1-month DAPT versus 4.3% in the 6-month DAPT historical control (Pnoninferiority = 0.0005). Bleeding Academic Research Consortium (BARC) types 2 to 5 bleeding was not significantly lower with 3- or 1-month DAPT, while BARC types 3 to 5 bleeding was reduced in both experimental groups. The rate of definite or probable stent thrombosis was 0.2% in XIENCE 90 (P < 0.0001 for the performance goal of 1.2%) and 0.3% in XIENCE 28.
CONCLUSIONS
Among HBR patients undergoing PCI with cobalt-chromium everolimus-eluting stents, DAPT for 1 or 3 months was noninferior to 6 or 12 months of DAPT for ischemic outcomes and may be associated with less major bleeding and a low incidence of stent thrombosis.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology |
UniBE Contributor: |
Windecker, Stephan |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1876-7605 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Nadia Biscozzo |
Date Deposited: |
20 Jan 2022 09:19 |
Last Modified: |
05 Dec 2022 15:59 |
Publisher DOI: |
10.1016/j.jcin.2021.07.016 |
PubMed ID: |
34503737 |
Uncontrolled Keywords: |
bleeding everolimus-eluting stent high bleeding risk percutaneous coronary intervention short DAPT thrombosis |
BORIS DOI: |
10.48350/163188 |
URI: |
https://boris.unibe.ch/id/eprint/163188 |
Actions (login required)
 |
Edit item |